Early trial tests new combo for tough blood cancers
NCT ID NCT02362035
Summary
This early-stage study tested the safety and initial effectiveness of combining two drugs, acalabrutinib and pembrolizumab, for people with various blood cancers. It involved 161 participants with conditions like lymphoma and leukemia. The main goal was to see if the combination was safe and could help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA ( FL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Tucson, Arizona, 85704, United States
-
Research Site
Los Angeles, California, 90095, United States
-
Research Site
Denver, Colorado, 80218, United States
-
Research Site
Washington D.C., District of Columbia, 20007, United States
-
Research Site
Niles, Illinois, 60714, United States
-
Research Site
Boston, Massachusetts, 2215, United States
-
Research Site
Rochester, Minnesota, 55905-0001, United States
-
Research Site
Omaha, Nebraska, 68198-7680, United States
-
Research Site
Columbus, Ohio, 43210, United States
-
Research Site
Greenville, South Carolina, 29605, United States
-
Research Site
Nashville, Tennessee, 37203, United States
-
Research Site
Dallas, Texas, 75246, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
San Antonio, Texas, 78217, United States
-
Research Site
Tyler, Texas, 75702, United States
-
Research Site
Fairfax, Virginia, 22031, United States
-
Research Site
Roanoke, Virginia, 24014, United States
-
Research Site
Vancouver, Washington, 98684, United States
-
Research Site
Yakima, Washington, 98902, United States
Conditions
Explore the condition pages connected to this study.